The radiosensitivity of lymphomas as well as the local targeted delivery of high doses of radiation make radioimmunotherapy (RIT) an attractive therapeutic option. RIT is indeed an underestimated tool. In follicular lymphoma (FL), RIT represents one of the most effective single agents. The two most commonly used radioimmunoconjugates are 90Y-ibritumomab tiuxetan (Zevalin®) and 131I-tositumomab, both based on murine anti-Cd20 antibodies. RIT has demonstrated efficacy in relapsed/refractory FL and was approved for this indication [1]. Subsequently, many trials have evaluated the role of RIT consolidation after initial tumor debulking with chemotherapy or immunochemotherapy [2] and several phase II studies supported these results [3–5]. We now report updated long-term efficacy and toxicity results of a multicenter nonrandomized phase II trial of fludarabine and mitoxantrone plus RIT (fludarabine, mitoxantrone, zevalin trial), demonstrating that this combination was safe and very effective in untreated FL patients.
Zinzani PL, Derenzini E, Pellegrini C, Rigacci L, Fabbri A, Gandolfi L, et al. (2012). Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). ANNALS OF ONCOLOGY, 23, 805-807 [10.1093/annonc/mdr633].
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).
ZINZANI, PIER LUIGI;DERENZINI, ENRICO;PELLEGRINI, CINZIA;GANDOLFI, LETIZIA;ARGNANI, LISA;CASADEI, BEATRICE;
2012
Abstract
The radiosensitivity of lymphomas as well as the local targeted delivery of high doses of radiation make radioimmunotherapy (RIT) an attractive therapeutic option. RIT is indeed an underestimated tool. In follicular lymphoma (FL), RIT represents one of the most effective single agents. The two most commonly used radioimmunoconjugates are 90Y-ibritumomab tiuxetan (Zevalin®) and 131I-tositumomab, both based on murine anti-Cd20 antibodies. RIT has demonstrated efficacy in relapsed/refractory FL and was approved for this indication [1]. Subsequently, many trials have evaluated the role of RIT consolidation after initial tumor debulking with chemotherapy or immunochemotherapy [2] and several phase II studies supported these results [3–5]. We now report updated long-term efficacy and toxicity results of a multicenter nonrandomized phase II trial of fludarabine and mitoxantrone plus RIT (fludarabine, mitoxantrone, zevalin trial), demonstrating that this combination was safe and very effective in untreated FL patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
